The Michelson Prizes are annual awards of $150,000, which support young investigators under the age of 35 who are using disruptive concepts and inventive processes to significantly advance human immunology and vaccine and immunotherapy discovery research for major global diseases. The Prizes are funded by the Michelson Medical Research Foundation and overseen by the Human Vaccines Project -- the application window for the 2021 Prizes will run from April 1 – June 18, 2021.
The 2021 Michelson Prizes will be looking for research proposals in two areas:
• Human Immunology and Vaccine Research: The committee will be looking for research aimed at tackling the current roadblocks that exist in human vaccine development and expanding our limited understanding of key immune processes that are fundamental to successful vaccine and immunotherapy development.
• Climate Change and Human Immunology: The committee is looking for research that expands our understanding of the potential effects of climate change on immune function with a particular interest in research that will directly translate into vaccine and immunotherapy development to mitigate its impact.
The selection committee will be looking to support research that is both highly innovative and has the potential for high impact. Specifically, projects should propose innovative ideas and approaches that can be applied across many disease areas and states. Projects should have the potential to significantly expand our understanding of the human immune system and accelerate the development of vaccines and immunotherapies.
While the Michelson Prizes are focused on research in the fields of immunology, vaccine and immunotherapy discovery, applicants from the full spectrum of related disciplines, including clinical research, biochemistry, molecular biology, protein engineering, computer science, artificial intelligence/machine learning, biophysics, environmental health, nanotechnology, etc., are encouraged to apply.
Additional info can be found at https://www.humanvaccinesproject.org/michelsonprizes/
The Global Health Network, EDCTP, and Women’s College Hospital at the University of Toronto have extended their partnership to provide continued access to the SPIRIT Electronic Protocol Tool and Resource (SEPTRE) platform. Through this collaboration, a limited number of free three-year licenses remain available for researchers in low- and middle-income countries (LMICs) who may not otherwise afford access.
SEPTRE is an online tool that helps researchers design, manage, and register high-quality clinical trial protocols in line with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines, which were updated in 2025. The update introduced new sections on open science, harms assessment, intervention descriptions, and patient and public involvement.
Applications can be submitted through the EDCTP Knowledge Hub SEPTRE enquiry form. Applicants should be located in a low- or middle-income country (preference is given to researchers based in Africa and who are members of the EDCTP Knowledge Hub). We encourage applicants via the form to state their goals and objectives to apply for a SEPTRE license and the research they want to undertake. Successful applicants agree that they will submit a yearly report on how they have made use of the license.
Learn more about the EDCTP Knowledge Hub.
Read moreThe EDCTP Association deeply mourns the loss of Professor Jean Louis Abdourahim Ndiaye, joining the global health community in honouring an outstanding researcher whose impact will continue to be felt across the global health research field.
Professor Ndiaye was awarded a Senior Fellowship in 2011 under the EDCTP1 programme to conduct research on seasonal malaria chemoprophylaxis (SMC). He led transformative malaria prevention research, including innovative seasonal intermittent preventive treatment in children (IPTc), and continued to develop his research on preventing and protecting children from malaria. At the University of Thiès, Senegal, he built a research team and went on to head the OPT-SMC project, funded under the EDCTP2 programme, which focused on strengthening the capacity of national malaria control programmes in conducting implementation research to improve SMC delivery and impact. This project supported 13 countries across West and Central Africa (Benin, Burkina Faso, Cameroon, Chad, The Gambia, Ghana, Guinea, Guinea-Bissau, Mali, Mauritania, Niger, Nigeria, Senegal, and Togo), bringing together national malaria programme representatives to share expertise and tailor interventions to local contexts.
Professor Ndiaye was not only a leading scientist but also a kind and humble man, deeply committed to reducing the burden of malaria in Africa and developing the next generation of African researchers. His contributions have made a significant impact on malaria control and implementation research. His passing is a considerable loss to the global scientific community, particularly in Africa. He will be deeply missed. We extend our condolences to his family, friends, and colleagues.
Read moreIn his EDCTP-GSK Senior Fellowship, Professor George Boateng Kyei of the Noguchi Memorial Institute for Medical Research, University of Ghana, has not only advanced the search for an HIV cure but also strengthened research capacity across Ghana and the broader African region.
HIV remains a pressing public health issue in Africa, with persistent challenges hindering the quest for a cure. This fellowship project focused on one such challenge: the virus’s ability to remain dormant within resting CD4+ T cells, even among individuals receiving antiretroviral therapy (ART). By exploring the innovative “shock and kill” approach, the research aimed to reactivate latent HIV and target infected cells for destruction. A notable scientific achievement was the identification and confirmation of three novel epigenetic compounds capable of reactivating latent HIV from virologically suppressed individuals. These findings pave the way for future studies in animal models, with the potential to transition into clinical trials aiming at finding a cure for HIV.
The establishment of a drug screening platform at the University of Ghana stands out as a long-term asset for HIV drug discovery and cure research. Additionally, the project introduced regular viral load monitoring for a substantial cohort of patients—an essential practice previously not standard in Ghana. The data generated from this monitoring has been instrumental in shaping national HIV treatment policies and improving patient care.
Furthermore, the project developed a biobank and a well-characterised cohort of HIV-infected adults, providing invaluable resources for ongoing and future HIV cure research. Insights gathered from patients regarding their perceptions of HIV cure research will inform the design and conduct of subsequent studies in Ghana and across Africa.
The impact of the fellowship extends beyond laboratory accomplishments; it has significantly influenced research training and career development. The fellowship helped nurture the growth of junior scientists, many of whom have evolved into independent research leaders, securing competitive grants and fellowships, such as the IAS Research-for-Cure Academy and NIH R21. They have presented their findings at prestigious international conferences, including the African Virology Congress and the American Society of Tropical Medicine and Hygiene (ASTMH).
Post-doctoral fellows have notably received fellowships from esteemed international programmes, such as the Science by Women Fellowship and the NIH CFAR Africure award, showcasing their growing prominence in the research community.
Professor Kyei’s mentorship has not gone unnoticed; in April 2024, he received special recognition from the University of Ghana’s Centre for Gender Studies and Advocacy (CEGENSA) for his outstanding mentorship of female academics—an honour highlighted by nominations from his own mentees. The project also celebrated the achievements of its team members, with one post-doc winning Best Senior Research Fellow at the 2024 NMIMR Awards and research assistants earning accolades at the 2024 African Virologist Conference.
Professor Kyei’s research has led to significant international visibility, with his team members winning travel awards to attend prestigious conferences, including the Keystone Symposium and the African Virology Congress. These opportunities have allowed them to present their findings and collaborate with global experts in the field.
The EDCTP-GSK Senior Fellowship grant has facilitated the groundwork for additional projects, including a newly awarded Fogarty grant aimed at enhancing HIV basic science and cure research training at the University of Ghana. This grant will train 17 researchers over the next 5 years, further strengthening the research landscape in Ghana.
As the team looks to the future, plans are in place to expand research into HIV reservoir characteristics among virologically suppressed patients across Ghana. This extension not only continues the momentum generated by the EDCTP grant, but also reinforces Ghana’s position as a leader in HIV cure research in Africa and contributes to the global effort to eradicate HIV.